{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:18:06Z","timestamp":1790720286102,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,2,17]],"date-time":"2007-02-17T00:00:00Z","timestamp":1171670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2007,2,17]],"date-time":"2007-02-17T00:00:00Z","timestamp":1171670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1007\/s00280-006-0397-0","type":"journal-article","created":{"date-parts":[[2007,2,16]],"date-time":"2007-02-16T01:39:18Z","timestamp":1171589958000},"page":"523-533","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":103,"title":["Phase I and pharmacokinetic trial of AP5346, a DACH\u2013platinum\u2013polymer conjugate, administered weekly for three out of every 4\u00a0weeks to advanced solid tumor patients"],"prefix":"10.1007","volume":"60","author":[{"given":"Mario","family":"Campone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeany M.","family":"Rademaker-Lakhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaafar","family":"Bennouna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Nowotnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H. M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,2,17]]},"reference":[{"key":"397_CR1","first-page":"3087","volume":"56","author":"S Aebi","year":"1996","unstructured":"Aebi S, Kurdi-Haidar B, Gordon R, Cenni B, Zheng H, Fink D, Christen R, Boland CR, Koi M, Fishel R, Howell SB (1996) Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56:3087","journal-title":"Cancer Res"},{"key":"397_CR2","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A de Gramont","year":"2000","unstructured":"de Gramont A, Figer A, Seymour M, et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938","journal-title":"J Clin Oncol"},{"key":"397_CR3","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1038\/sj.bjc.6602573","volume":"92","author":"F De Vita","year":"2005","unstructured":"De Vita F, Orditura M, Matano E, Bianco R, Carlomagno C, Infusino S, Damiano V, Simeone E, Diadema MR, Lieto E, Castellano P, Pepe S, De Placido S, Galizia G, Di Martino N, Ciardiello F, Catalano G, Bianco AR (2005) A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients. Br J Cancer 92:1644","journal-title":"Br J Cancer"},{"key":"397_CR4","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1093\/annonc\/mdg342","volume":"14","author":"JP Droz","year":"2003","unstructured":"Droz JP, Muracciole X, Mottet N, Ould Kaci M, Vannetzel JM, Albin N, Culine S, Rodier JM, Misset JL, Mackenzie S, Cvitkovic E, Benoit G (2003) Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients. Ann Oncol 14:1291","journal-title":"Ann Oncol"},{"key":"397_CR5","first-page":"262","volume":"7","author":"R Duncan","year":"1997","unstructured":"Duncan R (1997) Polymer therapeutics for tumour specific delivery. Chem Ind 7:262","journal-title":"Chem Ind"},{"key":"397_CR6","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/BF00684890","volume":"25","author":"JM Extra","year":"1990","unstructured":"Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25:299","journal-title":"Cancer Chemother Pharmacol"},{"key":"397_CR7","first-page":"1671","volume":"18","author":"A Gowda","year":"2004","unstructured":"Gowda A, Goel R, Berdzik J, Leichman CG, Javle M (2004) Hypersensitivity Reactions to oxaliplatin: incidence and management. Oncology (Williston Park) 18:1671","journal-title":"Oncology (Williston Park)"},{"key":"397_CR8","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.1995.13.7.1584","volume":"13","author":"T Kavanagh","year":"1995","unstructured":"Kavanagh T, Tresukosol D, Edwards C, Freedman R, Aagaard L, Gonzalez de Leon C, Fishman A, Mante R, Hord M, Kudelka A (1995) Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 13:1584","journal-title":"J Clin Oncol"},{"key":"397_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/mus.20340","volume":"32","author":"AV Krishnan","year":"2005","unstructured":"Krishnan AV, Goldstein D, Friedlander M, Kiernan MC (2005) Oxaliplatin-induced neurotoxicity and the development of neuropathy. Muscle Nerve 32:51","journal-title":"Muscle Nerve"},{"key":"397_CR10","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1200\/JCO.1999.17.4.1141","volume":"17","author":"M Markman","year":"1999","unstructured":"Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, Belinson J (1999) Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 17:1141","journal-title":"J Clin Oncol"},{"key":"397_CR11","first-page":"6387","volume":"46","author":"Y Matsumura","year":"1986","unstructured":"Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46:6387","journal-title":"Cancer Res"},{"key":"397_CR12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/bjc.1998.428","volume":"77","author":"JL Misset","year":"1998","unstructured":"Misset JL (1998) Oxaliplatin in practice. Br J Cancer 77 Suppl 4:4","journal-title":"Br J Cancer"},{"key":"397_CR13","doi-asserted-by":"crossref","unstructured":"Monnet I, de CH, Soulie P, Saltiel-Voisin S, Bekradda M, Saltiel JC, Brain E, Rixe O, Yataghene Y, Misset JL, Cvitkovic E (2002) Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study. Ann Oncol 13:103","DOI":"10.1093\/annonc\/mdf006"},{"key":"397_CR14","first-page":"57","volume":"6","author":"FM Muggia","year":"1996","unstructured":"Muggia FM (1996) Dose intensity: not the only path to clinical dose optimization. J Infus Chemother 6:57","journal-title":"J Infus Chemother"},{"key":"397_CR15","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1152\/physrev.1997.77.3.759","volume":"77","author":"S Mukherjee","year":"1997","unstructured":"Mukherjee S, Ghosh RN, Maxfield FR (1997) Endocytosis. Physiol Rev 77:759","journal-title":"Physiol Rev"},{"key":"397_CR16","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1200\/JCO.1991.9.7.1163","volume":"9","author":"CR Nichols","year":"1991","unstructured":"Nichols CR, Williams SD, Loehrer PJ, Greco FA, Crawford ED, Weetlaufer J, Miller ME, Bartolucci A, Schacter L, Einhorn LH (1991) Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer study group and Southwest oncology group protocol. J Clin Oncol 9:1163","journal-title":"J Clin Oncol"},{"key":"397_CR17","doi-asserted-by":"publisher","first-page":"3386","DOI":"10.1158\/1078-0432.CCR-03-0315","volume":"10","author":"JM Rademaker-Lakhai","year":"2004","unstructured":"Rademaker-Lakhai JM, Terret C, Howell SB, Baud CM, De Boer RF, Pluim D, Beijnen JH, Schellens JH, Droz JP (2004) A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res 10:3386","journal-title":"Clin Cancer Res"},{"key":"397_CR18","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1158\/1078-0432.CCR-05-2169","volume":"12","author":"JR Rice","year":"2006","unstructured":"Rice JR, Gerberich JL, Nowotnik DP, Howell SB (2006) Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin Cancer Res 12:2248","journal-title":"Clin Cancer Res"},{"key":"397_CR19","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1358\/dof.2004.029.06.816764","volume":"29","author":"JR Rice","year":"2004","unstructured":"Rice JR, Howell SB (2004) AP-5346. Polymer-delivered platinum complex. Drugs Future 29:561","journal-title":"Drugs Future"},{"key":"397_CR20","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/S0006-2952(97)81490-6","volume":"52","author":"O Rixe","year":"1996","unstructured":"Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T (1996) Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute\u2019s anticancer drug screen panel. Biochem Pharmacol 52:1855","journal-title":"Biochem Pharmacol"},{"key":"397_CR21","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1093\/carcin\/17.12.2763","volume":"17","author":"CP Saris","year":"1996","unstructured":"Saris CP, van de Vaart PJ, Rietbroek RC, Blommaert FA (1996) In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis 17:2763","journal-title":"Carcinogenesis"},{"key":"397_CR22","first-page":"135","volume":"6","author":"LW Seymour","year":"1992","unstructured":"Seymour LW (1992) Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Sys 6:135","journal-title":"Crit Rev Ther Drug Carrier Sys"},{"key":"397_CR23","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1093\/jnci\/89.15.1138","volume":"89","author":"R Simon","year":"1997","unstructured":"Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138","journal-title":"J Natl Cancer Inst"},{"key":"397_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New Guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205","journal-title":"J Natl Cancer Inst"},{"key":"397_CR25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229","journal-title":"J Clin Oncol"},{"key":"397_CR26","first-page":"3579","volume":"58","author":"A Vaisman","year":"1998","unstructured":"Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC, Hamilton TC, Chaney SG (1998) The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 58:3579","journal-title":"Cancer Res"},{"key":"397_CR27","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/annonc\/mdj097","volume":"17","author":"P Viens","year":"2006","unstructured":"Viens P, Petit T, Yovine A, Bougnoux P, Deplanque G, Cottu PH, Delva R, Lotz JP, Belle SV, Extra JM, Cvitkovic E (2006) A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. Ann Oncol 17:429","journal-title":"Ann Oncol"},{"key":"397_CR28","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1124\/mol.58.5.920","volume":"58","author":"JM Woynarowski","year":"2000","unstructured":"Woynarowski JM, Faivre S, Herzig MC, Arnett B, Chapman WG, Trevino AV, Raymond E, Chaney SG, Vaisman A, Varchenko M, Juniewicz PE (2000) Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 58:920","journal-title":"Mol Pharmacol"},{"key":"397_CR29","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1200\/JCO.2002.06.164","volume":"20","author":"L Zelek","year":"2002","unstructured":"Zelek L, Cottu P, Tubiana-Hulin M, Vannetzel JM, Chollet P, Misset JL, Chouaki N, Marty M, Gamelin E, Culine S, Dieras V, Mackenzie S, Spielmann M (2002) Phase II study of oxaliplatin and fluorouracil in taxane\u2013and anthracycline-pretreated breast cancer patients. J Clin Oncol 20:2551","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-006-0397-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-006-0397-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-006-0397-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-006-0397-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T02:40:45Z","timestamp":1652582445000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-006-0397-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,17]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["397"],"URL":"https:\/\/doi.org\/10.1007\/s00280-006-0397-0","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,17]]},"assertion":[{"value":"14 September 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2006","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}